TY  - GEN
AU  - Calvo de Juan, V.
AU  - Cobo Dols, M.
AU  - Rodriguez-Abreu, D.
AU  - Carcereny, E.
AU  - Cantero, A.
AU  - Bernabe Caro, R.
AU  - Benitez Lopez, G.
AU  - Lopez Castro, R.
AU  - Massuti Sureda, B.
AU  - del Barco, E.
AU  - Garcia Campelo, M. R.
AU  - Guirado, M.
AU  - Camps Herrero, C. J. C.
AU  - Ortega Granados, A. L. O.
AU  - Gonzalez-Larriba, J. L.
AU  - Sanchez Hernandez, A.
AU  - Gonzalez Ojea, C.
AU  - Sala Gonzalez, M. A.
AU  - Juan Vidal, O. J.
AU  - Provencio Pulla, M.
PY  - 2022
DO  - 10.1016/j.annonc.2022.02.048
SN  - 0923-7534
UR  - http://hdl.handle.net/10668/21890
T2  - Annals of oncology
AB  - Background: The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted therapies available for advanced stages and the emergence of immunotherapy itself. This...
LA  - en
PB  - Elsevier
KW  - Biomarkers
KW  - Testing
KW  - Metastatic lung cancer
KW  - Targeted therapies
KW  - Lung Neoplasms
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Protein-Tyrosine Kinases
KW  - Proto-Oncogene Proteins B-raf
KW  - Proto-Oncogene Proteins p21(ras)
KW  - Biomarkers, Tumor
KW  - Spain
KW  - Cost-Benefit Analysis
TI  - Determination of essential biomarkers in lung cancer: A real-world data study in Spain
TY  - RESEARCH
VL  - 33
ER  -